Company: BIAF
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023405
Chunk: 23

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 8
Chunk 23
---
 exercised, the Company included the renewal term in the total lease term used in calculating the right-of-use
asset and lease liability.

    14

The
components of lease expense, which are included in selling, general and administrative expense and depreciation and amortization for
the three and nine months ended September 30, 2025 and 2024, are as follows:

SCHEDULE OF COMPONENTS OF LEASE EXPENSE

    2025  
    2024  
    2025  
    2024 

    Three months ended
                                                                                September 30,  
    Nine months ended
                                                                                September 30, 

    2025  
    2024  
    2025  
    2024 
  
    Amortization of right-of-use asset - finance lease 
    $54,177  
    $96,243  
    $204,597  
    $288,729 
  
    Interest on lease liabilities - finance lease 
     3,227  
     21,533  
     23,718  
     67,318 
  
    Operating lease cost 
     39,764  
     33,198  
     119,293  
     93,029 
  
    Total lease cost 
    $97,168  
    $150,974  
    $347,608  
    $449,076 

    Cash paid for amounts included in the measurement of lease liabilities: 

    Operating cash flows from finance leases 
    $(58,031) 
    $(91,038) 
    $(251,272) 
    $(270,143)
  
    Operating cash flows from operating leases 
     (38,220) 
     (203) 
     (94,458) 
     (1,235)

SCHEDULE OF BALANCE SHEET INFORMATION RELATING TO LEASES

    Operating leases: 
    September 30, 2025  
    December 31, 2024 
  
    Operating lease right-of-use, assets 
    $367,398  
    $463,011 
  
    Operating lease liability, current 
    $136,197  
    $127,498 
  
    Operating lease liability, non-current 
     238,942  
     342,098 
  
    Total operating lease liabilities 
    $375,139  
    $